Alcolase
Alcolase is developing a liposomal enzyme system designed to break down alcohol and acetaldehyde in the stomach before it reaches the bloodstream. The supplement is specifically targeted at the 540 million people worldwide with an ALDH2 deficiency who experience alcohol intolerance. The company is initially focusing its market entry on Singapore and South Korea.
Visit websiteCopenhagen, Denmark
Biotech
Healthtech
Consumer Health
Funding summary
- Total raised
- €1.5M
- Funding rounds
- 1
Investors in Alcolase
Investors on record for Alcolase. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Alcolase?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors